A Phase III, Open Label, Two-Arm, Parallel Design, Randomized, Multicenter Study Evaluating the Safety and Efficacy of 25 mg and 50 mg Doses of Proellex® (CDB-4124) to Assess Recurrence of Symptoms in the Treatment of Premenopausal Women With Symptomatic Uterine Fibroids
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
To evaluate the safety of 25 and 50 mg Proellex administered once daily for two treatment cycles
Four months each cycle
Yes
Andre van As, MD, PhD
Study Director
Repros Therapeutics Inc.
United States: Food and Drug Administration
ZPU-306
NCT00874302
Name | Location |
---|---|
Meharry Medical College | Nashville, Tennessee 37208-3599 |
Lyndhurst Gynecologic Associates | Winston-Salem, North Carolina 27103 |
Clinical Trials of America | Eugene, Oregon 97401 |
Genesis Center for Clinical Research | San Diego, California 92103 |
Physician Care Clinical Research, LLC | Sarasota, Florida 34329 |
Soapstone Center for Clinical Research | Decatur, Georgia 30034 |
York Clinical Consulting | Marrero, Louisiana 70072 |
Female Pelvic Medicine | Grand Rapids, Michigan 49503 |
Hawthorne Medical Research, Inc. | Winston-Salem, North Carolina 27103 |
Thomas Jefferson University - Jefferson Center for Women's Medical Specialties | Philadelphia, Pennsylvania 19107-5127 |
Women's Care Center, PLC Research Memphis Associates | Memphis, Tennessee 38119 |
Willowbend Health & Wellness Associates | Plano, Texas 75093 |
Atlanta Women's Research Inst. | Atlanta, Georgia 30342 |